The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective.

Chemical probes represent an important component of both academic and pharmaceutical drug discovery research. As a complement to prior reviews that have defined this scientific field, we aim to provide an industry perspective on the value of having high-quality chemical probes throughout the course of preclinical research. By studying examples from the internal Merck pipeline, we recognize that these probes require significant collaborative investment to realize their potential impact in clarifying the tractability and translation of a given therapeutic target. This perspective concludes with recommendations for chemical probe discovery aimed toward maximizing their potential to identify targets that result in the successful delivery of novel therapeutics.

[1]  A. Hezel,et al.  Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005) , 2015, Cancer.

[2]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[3]  Mark E Bunnage,et al.  Target validation using chemical probes. , 2013, Nature chemical biology.

[4]  P. Coleman,et al.  Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. , 2016, Journal of medicinal chemistry.

[5]  D. Altshuler,et al.  Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.

[6]  K. K. Nanda,et al.  Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy. , 2011, Bioorganic & medicinal chemistry letters.

[7]  C. Schnell,et al.  LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice , 2011, Human molecular genetics.

[8]  William A Weiss,et al.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.

[9]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[10]  R. Pederson,et al.  Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide , 1998, Diabetes.

[11]  Zhijian Zhao,et al.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[12]  A. Dilella,et al.  Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist. , 2007, Journal of medicinal chemistry.

[13]  C. Wiesmann,et al.  The discovery of first-in-class drugs: origins and evolution , 2014, Nature Reviews Drug Discovery.

[14]  A. Marchand,et al.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.

[15]  D. Hazuda,et al.  Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase , 1997, Journal of virology.

[16]  D. Henze,et al.  Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia. , 2011, Bioorganic & medicinal chemistry letters.

[17]  N. Thornberry,et al.  Discovery of JANUVIA TM (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes. , 2007 .

[18]  Lynn A. Hyde,et al.  MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[19]  J. Arrowsmith.  Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.

[20]  Philip C Biggin,et al.  Discovery of the First Selective, Nonpeptidic Orexin 2 Receptor Agonists. , 2015, Journal of medicinal chemistry.

[21]  Arthur S Slutsky,et al.  Preclinical target validation using patient-derived cells , 2015, Nature Reviews Drug Discovery.

[22]  J. Renger,et al.  Proline bis-amides as potent dual orexin receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[23]  Massimiliano Beltramo.  Cannabinoid type 2 receptor as a target for chronic - pain. , 2009, Mini reviews in medicinal chemistry.

[24]  Ian Collins,et al.  Probing the Probes: Fitness Factors For Small Molecule Tools , 2010, Chemistry & biology.

[25]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[26]  D. Luckenbaugh,et al.  A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder , 2012, Journal of clinical psychopharmacology.

[27]  J. Qiu,et al.  Mature B Cells Are Critical to T-cell-mediated Tumor Immunity Induced by an Agonist Anti-GITR Monoclonal Antibody , 2010, Journal of immunotherapy.

[28]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[29]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[30]  J. Krawczyk,et al.  AKT as a therapeutic target in multiple myeloma , 2014, Expert opinion on therapeutic targets.

[31]  N. Thornberry,et al.  Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2007, Current topics in medicinal chemistry.

[32]  R. M. Stewart,et al.  Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease , 2009, Journal of clinical pharmacology.

[33]  K. Scearce-Levie,et al.  Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. , 2012, Journal of medicinal chemistry.

[34]  C. Lindsley,et al.  Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. , 2005, Molecular cancer therapeutics.

[35]  J. Graff.  Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma , 2002, Expert opinion on therapeutic targets.